August 28, 2016 8:38 AM ET

Healthcare Providers and Services

Company Overview of City Of Hope

Company Overview

City of Hope, a nonprofit public benefit corporation, operates City of Hope National Medical Center (the Center), City of Hope Medical Foundation, and Beckman Research Institute of the City of Hope. The Center operates a 186-bed tertiary referral center primarily for the treatment of cancer, diabetes, and other life-threatening diseases in Duarte, California. The company was founded in 1913 and is based in Duarte, California.

1500 East Duarte Road

Duarte, CA 91010

United States

Founded in 1913



Key Executives for City Of Hope

Chief Executive Officer and President
Chief Financial Officer
Age: 53
Chief Operating Officer and Executive Vice President
Chief Scientific Officer and Provost
Senior Vice President of Research Operations
Compensation as of Fiscal Year 2016.

City Of Hope Key Developments

City of Hope and Novonco Therapeutics Inc. Announces First-In-Human Clinical Trial for COH29

City of Hope and Novonco Therapeutics Inc. announced the initiation of a phase 1, first-in-human clinical trial for a promising anti-cancer drug – COH29 – that will be used to treat patients with solid tumors, including breast, colon, ovarian, pancreatic, stomach and lung cancers. Patients whose disease is treatment-resistant to standard therapies, or for which no other treatment options exist, are eligible for the trial. City of Hope has conducted preclinical studies with the chemotherapy drug, which inhibits activity of an enzyme called ribonucleotide reductase (RNR), thus preventing cancer cells from copying themselves and dividing. By designing the drug to target RNR, researchers also hope that COH29 will produce fewer side effects than other chemotherapy drugs currently available, and that cancer cells are less likely to develop a resistance to the agent. In preclinical studies, COH29 has demonstrated efficacy against leukemia and ovarian cancer cells. These early findings are encouraging for finding treatments for these diseases that are difficult to treat and for which new approaches are desperately needed. It has also shown promise against breast cancer cells. One long-term goal is to develop COH29 into a new therapy for ovarian cancer, which is the most lethal – and second most common – gynecologic cancer in the United States. COH29 was the first small molecule produced in City of Hope’s Chemical GMP (good manufacturing practice) Synthesis Facility, a manufacturing resource for small and large molecule therapeutics for clinical trials. Researchers first searched the National Cancer Institute’s library of anti-cancer agents to find a promising anti-cancer compound, and then used data obtained with the help of City of Hope’s Core Services’ laboratory scientists to make structural adjustments to improve the molecule and test its effectiveness in preclinical studies.

Kety Duron Joins City of Hope as Chief Human Resources and Diversity Officer

Accomplished human resources executive Kety Duron has joined City of Hope as chief human resources and diversity officer. Duron will provide executive and strategic oversight for all of City of Hope's human resources initiatives. She is a member of the Executive Team and reports to Robert W. Stone, president and chief executive officer. Most recently, Duron was vice president of human resources at Stanford Health Care where she transformed the department into a customer-focused, proactive thought-partner. Prior to her work at Stanford Health Care, she served in a variety of human resources leadership roles at UCLA Health for more than 25 years. At City of Hope, Duron will be responsible for all areas of human resources, including compensation, benefits, employee/labor relations, organizational design, development and effectiveness, succession planning and leadership development, training and development, talent acquisition and selection, workforce planning, performance management and diversity.

Ravi Salgia Joins City of Hope as Chair of Medical Oncology

Medical oncologist and researcher Ravi Salgia, M.D., Ph.D., has joined City of Hope as a professor and chair in the Department of Medical Oncology & Therapeutics Research. He will play a key leadership role in the expansion of clinical programs at City of Hope's Duarte campus and in its clinics throughout Southern California, as well as enhance the integration of therapeutics with research. At City of Hope, Salgia will work closely with faculty to support both basic research and clinical studies aimed at discovering new cancer treatments. Beyond his role as the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology, he will also serve as associate director for clinical sciences in the institution's comprehensive cancer center. His expertise in developing new cancer treatments in the laboratory, testing them in clinical trials and speeding them to patients fits perfectly with City of Hope's mission.

Similar Private Companies By Industry

Company Name Region
@ Home Medical, Inc. United States
@home approach, llc United States
@Home Care United States
1011 E. Pecan Grove Road, LLC United States
1125 Sir Francis Drake Boulevard Operating Company, Llc United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact City Of Hope, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at